

[Partnering](#)

[Media](#)

[Careers](#)

[Contact](#)

Radius



INVESTOR RELATIONS

[Overview](#)

[Press Releases](#)

[Events & Presentations](#)

[Corporate Governance](#)



[Financials & Filings](#)

[Stock Information](#)

[Investor FAQs](#)

[Investment Inquiries](#)

Investor Relations



Corporate Profile

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, MYMLOS® (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer.

Press Releases

Oct 12, 2018

[Radius Health to Announce Third Quarter 2018 Financial Results, Host Conference Call and Live Webcast on November 1, 2018](#)

Oct 03, 2018

[Radius Health Announces Latest 2019 Medicare Part D Coverage for TYMLOS® \(abaloparatide\) Injection](#)

[View all press releases »](#)

Events & Presentations

Nov 1, 2018 at 8:00 AM EDT

[Q3 Radius Health Inc Earnings Conference Call](#)

Oct 3, 2018 at 11:00 AM EDT

[Leerink Partners Roundtable Series: Rare Disease & Oncology](#)

[View all events & presentations »](#)



Search

[Investors](#)

[Overview](#)

[Press Releases](#)

[Events & Presentations](#)

[Corporate Governance](#)

[Careers](#)

[Products](#)

[Pipeline](#)

Day Connected



[R&D](#)

[Terms of Use](#) [Privacy Policy](#)

[Financials & Filings](#)

[Stock Information](#)

[Investor FAQs](#)

[Investment Inquiries](#)

[Partnering](#)

[Media](#)

[Contact](#)

This site is intended for United States residents only.

© 2018 Radius Health, Inc. RADIUS and TYMLOS are registered trademarks of Radius Health, Inc.

All other trademarks are the property of their respective owners.